NCT01939184

Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 796 (actual)
• Sponsor: Warner Chilcott · Industry
• Sex: Male
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of various fixed daily doses of WC3055 compared with placebo for the treatment of subjects with LUTS secondary to BPH.

Conditions

• Benign Prostatic Hyperplasia

Interventions

Type	Name	Description
DRUG	WC3055	12.5, 25, 50 or 75 mg dose
OTHER	Placebo	Placebo

Timeline

• Start date: 2013-08-01
• Primary completion: 2014-03-01
• Completion: 2014-04-01
• First posted: 2013-09-11
• Last updated: 2015-06-29

Locations

95 sites across 1 country: United States